5 research outputs found
RNA-seq discovery, functional characterization, and comparison of sesquiterpene synthases from Solanum lycopersicum and Solanum habrochaites trichomes
Solanum lycopersicum and Solanum habrochaites (f. typicum) accession PI127826 emit a variety of sesquiterpenes. To identify terpene synthases involved in the production of these volatile sesquiterpenes, we used massive parallel pyrosequencing (RNA-seq) to obtain the transcriptome of the stem trichomes from these plants. This approach resulted initially in the discovery of six sesquiterpene synthase cDNAs from S. lycopersicum and five from S. habrochaites. Searches of other databases and the S. lycopersicum genome resulted in the discovery of two additional sesquiterpene synthases expressed in trichomes. The sesquiterpene synthases from S. lycopersicum and S. habrochaites have high levels of protein identity. Several of them appeared to encode for non-functional proteins. Functional recombinant proteins produced germacrenes, Ī²-caryophyllene/Ī±-humulene, viridiflorene and valencene from (E,E)-farnesyl diphosphate. However, the activities of these enzymes do not completely explain the differences in sesquiterpene production between the two tomato plants. RT-qPCR confirmed high levels of expression of most of the S. lycopersicum sesquiterpene synthases in stem trichomes. In addition, one sesquiterpene synthase was induced by jasmonic acid, while another appeared to be slightly repressed by the treatment. Our data provide a foundation to study the evolution of terpene synthases in cultivated and wild tomato
High-Throughput Detection of Induced Mutations and Natural Variation Using KeyPointā¢ Technology
Reverse genetics approaches rely on the detection of sequence alterations in target genes to identify allelic variants among mutant or natural populations. Current (pre-) screening methods such as TILLING and EcoTILLING are based on the detection of single base mismatches in heteroduplexes using endonucleases such as CEL 1. However, there are drawbacks in the use of endonucleases due to their relatively poor cleavage efficiency and exonuclease activity. Moreover, pre-screening methods do not reveal information about the nature of sequence changes and their possible impact on gene function. We present KeyPointā¢ technology, a high-throughput mutation/polymorphism discovery technique based on massive parallel sequencing of target genes amplified from mutant or natural populations. KeyPoint combines multi-dimensional pooling of large numbers of individual DNA samples and the use of sample identification tags (āsample barcodingā) with next-generation sequencing technology. We show the power of KeyPoint by identifying two mutants in the tomato eIF4E gene based on screening more than 3000 M2 families in a single GS FLX sequencing run, and discovery of six haplotypes of tomato eIF4E gene by re-sequencing three amplicons in a subset of 92 tomato lines from the EU-SOL core collection. We propose KeyPoint technology as a broadly applicable amplicon sequencing approach to screen mutant populations or germplasm collections for identification of (novel) allelic variation in a high-throughput fashion
A Novel Framework for Phenotyping Children With Suspected or Confirmed Infection for Future Biomarker Studies
Copyright Ā© 2021 Nijman, Oostenbrink, Moll, Casals-Pascual, von Both, Cunnington, De, Eleftheriou, Emonts, Fink, van der Flier, de Groot, Kaforou, Kohlmaier, Kuijpers, Lim, Maconochie, Paulus, Martinon-Torres, Pokorn, Romaine, Calle, Schlapbach, Smit, Tsolia, Usuf, Wright, Yeung, Zavadska, Zenz, Levin, Herberg, Carrol and the PERFORM consortium (Personalized Risk assessment in febrile children to optimize Real-life Management across the European Union).Background: The limited diagnostic accuracy of biomarkers in children at risk of a serious bacterial infection (SBI) might be due to the imperfect reference standard of SBI. We aimed to evaluate the diagnostic performance of a new classification algorithm for biomarker discovery in children at risk of SBI. Methods: We used data from five previously published, prospective observational biomarker discovery studies, which included patients aged 0ā <16 years: the Alder Hey emergency department (n = 1,120), Alder Hey pediatric intensive care unit (n = 355), Erasmus emergency department (n = 1,993), Maasstad emergency department (n = 714) and St. Mary's hospital (n = 200) cohorts. Biomarkers including procalcitonin (PCT) (4 cohorts), neutrophil gelatinase-associated lipocalin-2 (NGAL) (3 cohorts) and resistin (2 cohorts) were compared for their ability to classify patients according to current standards (dichotomous classification of SBI vs. non-SBI), vs. a proposed PERFORM classification algorithm that assign patients to one of eleven categories. These categories were based on clinical phenotype, test outcomes and C-reactive protein level and accounted for the uncertainty of final diagnosis in many febrile children. The success of the biomarkers was measured by the Area under the receiver operating Curves (AUCs) when they were used individually or in combination. Results: Using the new PERFORM classification system, patients with clinically confident bacterial diagnosis (ādefinite bacterialā category) had significantly higher levels of PCT, NGAL and resistin compared with those with a clinically confident viral diagnosis (ādefinite viralā category). Patients with diagnostic uncertainty had biomarker concentrations that varied across the spectrum. AUCs were higher for classification of ādefinite bacterialā vs. ādefinite viralā following the PERFORM algorithm than using the āSBIā vs. ānon-SBIā classification; summary AUC for PCT was 0.77 (95% CI 0.72ā0.82) vs. 0.70 (95% CI 0.65ā0.75); for NGAL this was 0.80 (95% CI 0.69ā0.91) vs. 0.70 (95% CI 0.58ā0.81); for resistin this was 0.68 (95% CI 0.61ā0.75) vs. 0.64 (0.58ā0.69) The three biomarkers combined had summary AUC of 0.83 (0.77ā0.89) for ādefinite bacterialā vs. ādefinite viralā infections and 0.71 (0.67ā0.74) for āSBIā vs. ānon-SBI.ā Conclusion: Biomarkers of bacterial infection were strongly associated with the diagnostic categories using the PERFORM classification system in five independent cohorts. Our proposed algorithm provides a novel framework for phenotyping children with suspected or confirmed infection for future biomarker studies.publishersversionPeer reviewe
A Novel Framework for Phenotyping Children With Suspected or Confirmed Infection for Future Biomarker Studies
Background: The limited diagnostic accuracy of biomarkers in children at
risk of a serious bacterial infection (SBI) might be due to the
imperfect reference standard of SBI. We aimed to evaluate the diagnostic
performance of a new classification algorithm for biomarker discovery in
children at risk of SBI.
Methods: We used data from five previously published, prospective
observational biomarker discovery studies, which included patients aged
0-<16 years: the Alder Hey emergency department (n = 1,120), Alder Hey
pediatric intensive care unit (n = 355), Erasmus emergency department (n
= 1,993), Maasstad emergency department (n = 714) and St. Maryās
hospital (n = 200) cohorts. Biomarkers including procalcitonin (PCT) (4
cohorts), neutrophil gelatinase-associated lipocalin-2 (NGAL) (3
cohorts) and resistin (2 cohorts) were compared for their ability to
classify patients according to current standards (dichotomous
classification of SBI vs. non-SBI), vs. a proposed PERFORM
classification algorithm that assign patients to one of eleven
categories. These categories were based on clinical phenotype, test
outcomes and C-reactive protein level and accounted for the uncertainty
of final diagnosis in many febrile children. The success of the
biomarkers was measured by the Area under the receiver operating Curves
(AUCs) when they were used individually or in combination.
Results: Using the new PERFORM classification system, patients with
clinically confident bacterial diagnosis (ādefinite bacterialā
category) had significantly higher levels of PCT, NGAL and resistin
compared with those with a clinically confident viral diagnosis
(ādefinite viralā category). Patients with diagnostic uncertainty
had biomarker concentrations that varied across the spectrum. AUCs were
higher for classification of ādefinite bacterialā vs. ādefinite
viralā following the PERFORM algorithm than using the āSBIā vs.
ānon-SBIā classification; summary AUC for PCT was 0.77 (95% CI
0.72-0.82) vs. 0.70 (95% CI 0.65-0.75); for NGAL this was 0.80 (95% CI
0.69-0.91) vs. 0.70 (95% CI 0.58-0.81); for resistin this was 0.68
(95% CI 0.61-0.75) vs. 0.64 (0.58-0.69) The three biomarkers combined
had summary AUC of 0.83 (0.77-0.89) for ādefinite bacterialā vs.
ādefinite viralā infections and 0.71 (0.67-0.74) for āSBIā vs.
ānon-SBI.ā
Conclusion: Biomarkers of bacterial infection were strongly associated
with the diagnostic categories using the PERFORM classification system
in five independent cohorts. Our proposed algorithm provides a novel
framework for phenotyping children with suspected or confirmed infection
for future biomarker studies